How big is the Global Fungal Keratitis Treatment Market?

The Global Fungal Keratitis Treatment Market size is expected to reach USD 0.86 billion in 2024 and grow at a CAGR of 4.60% to reach USD 1.07 billion by 2029. Read More

What is the current Global Fungal Keratitis Treatment Market size?

In 2024, the Global Fungal Keratitis Treatment Market size is expected to reach USD 0.86 billion. Read More

Who are the key players in Global Fungal Keratitis Treatment Market?

Merck & Co. Inc. , Bausch Health, Gilead Biosciences , Pfizer Inc. and Glenmark Pharmaceuticals are the major companies operating in the Global Fungal Keratitis Treatment Market. Read More

Which is the fastest growing region in Global Fungal Keratitis Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global Fungal Keratitis Treatment Market?

In 2024, the North America accounts for the largest market share in Global Fungal Keratitis Treatment Market. Read More

What years does this Global Fungal Keratitis Treatment Market cover, and what was the market size in 2023?

In 2023, the Global Fungal Keratitis Treatment Market size was estimated at USD 0.82 billion. The report covers the Global Fungal Keratitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Fungal Keratitis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Global Fungal Keratitis Treatment Market Share

Statistics for the 2023 & 2024 Global Fungal Keratitis Treatment market share, created by Mordor Intelligence™ Industry Reports. Global Fungal Keratitis Treatment share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Global Fungal Keratitis Treatment Industry

The Fungal Keratitis Treatment Market is moderately competitive. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc., Leadiant Biosciences, Gilead Biosciences, Inc., Bausch Health, Novo Holdings A/S (Xellia Pharmaceuticals), Alvogen, and Merck & Co. Inc. The companies are evolving through various strategies such as mergers and acquisitions, collaborations, and partnerships, along with investment in research and development activities to secure the position in the competitive market. For instance, in October 2019, Eyevance Pharmaceuticals announced the acquisition of TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% and NATACYN (natamycin ophthalmic suspension) 5% from Novartis.